CLINICAL TRIALS PROFILE FOR MOMELOTINIB DIHYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for momelotinib dihydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00935987 ↗ | Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | Completed | Gilead Sciences | Phase 1/Phase 2 | 2009-11-01 | This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV or post-ET. |
| NCT00935987 ↗ | Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | Completed | Sierra Oncology, Inc. | Phase 1/Phase 2 | 2009-11-01 | This study seeks to (i) determine a safe and tolerated dose of CYT387 (momelotinib) given to patients with PMF, post-PV or post-ET and, (ii) assess the effectiveness of orally-administered CYT387 as a treatment for PMF, post-PV or post-ET. |
| NCT01236638 ↗ | Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | Completed | Gilead Sciences | Phase 2 | 2010-11-01 | This extension protocol to the core study CCL09101 allows patients who have tolerated the drug and derived a clinical benefit, to continue to receive treatment beyond the 9 cycles of the core protocol. Long term safety and efficacy of CYT387 (momelotinib) will be evaluated. |
| NCT01236638 ↗ | Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) | Completed | Sierra Oncology, Inc. | Phase 2 | 2010-11-01 | This extension protocol to the core study CCL09101 allows patients who have tolerated the drug and derived a clinical benefit, to continue to receive treatment beyond the 9 cycles of the core protocol. Long term safety and efficacy of CYT387 (momelotinib) will be evaluated. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for momelotinib dihydrochloride
Condition Name
| Condition Name for momelotinib dihydrochloride | |
| Intervention | Trials |
| Primary Myelofibrosis | 8 |
| Post-essential Thrombocythemia Myelofibrosis | 7 |
| Post-Polycythemia Vera Myelofibrosis | 6 |
| Primary Myelofibrosis (PMF) | 3 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for momelotinib dihydrochloride
Trials by Country
Clinical Trial Progress for momelotinib dihydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for momelotinib dihydrochloride
Sponsor Name
